Gara Jalqabaatti › Luukemiya Limfoositiikii Keessummaa › North Carolina › Winston-Salem
Qorannoo klinikaalii Luukemiya Limfoositiikii Keessummaa Winston-Salem, NC keessatti
Qorannoo 8 Luukemiya Limfoositiikii Keessummaa f Winston-Salem fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Winston-Salem
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Namoota walitti qabaa jiraSadarkaa 3
- Atrium Health Wake Forest Baptist, Winston-Salem
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Namoota walitti qabaa jiraSadarkaa 3
- Atrium Health Wake Forest Baptist, Winston-Salem
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Namoota walitti qabaa jiraSadarkaa 2
- Novant Health Cancer Institute, Winston-Salem
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Namoota walitti qabaa jiraSadarkaa 2
- Research Site, Winston-Salem
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Namoota walitti qabaa jiraQorannoo ilaalaa
- Wake Forest Baptist Health, Winston-Salem
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Namoota walitti qabaa jiraSadarkaa 3
- Atrium Health Wake Forest Baptist Medical Center /ID# 273142, Winston-Salem
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Namoota walitti qabaa jiraSadarkaa 2
- Novant Health Forsyth Medical Center /ID# 249533, Winston-Salem
Qorannoo Luukemiya Limfoositiikii Keessummaa magaalota biroo keessatti
- Boston, MAQorannoo 31
- Columbus, OHQorannoo 28
- Durham, NCQorannoo 27
- Washington, DCQorannoo 22
- Seattle, WAQorannoo 20
- Rochester, MNQorannoo 18
- New York City, NYQorannoo 18
- Houston, TXQorannoo 17
- Baldwin Park, CAQorannoo 16
- Milwaukee, WIQorannoo 15
- Chicago, ILQorannoo 14
- Cincinnati, OHQorannoo 14
Qorannoo biroo Winston-Salem keessatti
- Saree (Gosoota Hunda)Qorannoo 19
- Leukemia Myeloidii HamaaQorannoo 18
- Myeloma Baay’eeQorannoo 14
- Saree OljooQorannoo 14
- Dhibee Onneessaa fi DhiigaQorannoo 14
- Kansara Qara'a Non-Small CellQorannoo 12
- COPDQorannoo 10
- Kansarii OvariiQorannoo 10
- Sukkaraa Gosa 2Qorannoo 9
- Myelodysplastic SyndromesQorannoo 9
- GlioblastomaQorannoo 8
- Dhibee QaraQorannoo 8
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.